Heart failure (HF) has been a staggering healthcare issue currently affecting more than 60
million people worldwide.** 1 Apart from non-pharmacologic interventions, the mainstay …

Background Angiotensin receptor blocker and a neprilysin inhibitor (ARNI) has emerged as
an innovative therapy for patients of heart failure with reduced ejection fraction (HFrEF). The …

Background: Sacubitril/Valsartan is one of the pillars of heart failure (HF) management. Little
is known about its uses or impact in real-world practice in the Indian population. We …

Heart failure (HF) is a leading cause of mortality and morbidity across the globe. High
prevalence, frequent hospitalization, longterm healthcare, absenteeism from work, and …

Objective: Clinical trial data on sacubitril/valsartan are important. Considering that real-world
data have important clinical implications, we aimed to report the efficacy and safety of …

Introduction The PARADIGM-HF trial in 2014 established sacubitril/valsartan (SV) as an
effective treatment for heart failure (HF). Recent trials support expanding its use and …

Objectives To determine efficacy and safety of sacubitril/valsartan compared with enalapril in
Indian patients of PARADIGM-HF trial. Methods A randomized, double-blind, active …

The article by Yandrapalli et al1 discusses 8 main limitations of LCZ696 (sacubitril/valsartan)
in the management of patients with heart failure with reduced ejection fraction (HFrEF) …

Objective To describe the efficacy, superiority and safety profile of the first-in-class
angiotensin receptor-neprilysin inhibitor “Sacubitril/Valsartan” as compared to angiotensin …

Heart failure is a condition in which the heart is unable to supply blood throughout the body.
Heart failure [HF] is one of the main healthcare burdens in the world and is more lethal than …